Sofwave Medical Ltd. (SOFW) Q3 Revenue Rises 35% to $28.5M

What happened

Sofwave reported third-quarter revenue of $28.5M, up 35% from a year earlier, and recurring usage-fee revenue of $13.3M, up 60%. It received China NMPA approval with an initial order for 70 systems; 10 shipped in the quarter and 60 are scheduled for the fourth quarter.

Confirmed

Global impact / market context

Faster growth in usage fees, which are recurring payments tied to how often the machines are used, suggests customers are treating more patients rather than just buying equipment. If that continues, revenue becomes steadier and less dependent on one-off system sales each quarter.

Analyst inference

The company also reported nine-month revenue up 41% to $82.9M, so this quarter extends an existing growth trend rather than starting a new one. China is a new market just opening, and the 60 systems still to ship are the next measurable test of that rollout.

Analyst inference

What to watch

1. The company plans to ship the remaining 60 China systems in the fourth quarter, so those shipments will show whether the initial order converts into recorded revenue on schedule. Confirmed
2. Watch whether usage-fee revenue keeps growing near 60%, since continued growth would show treatment volumes are rising and recurring revenue is becoming a larger share of the total. Analyst inference
3. Evidence of wider physician adoption in China, such as reorders or new clinic customers, would show the approval is building a lasting market rather than a single initial order. Proposed

Evidence

• globenewswire.com